2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Neil L. Berinstein, MD, professor, University of Toronto, Sunnybrook Health Sciences Centre, discusses combination treatments for patients with high-risk or recurrent follicular lymphoma.
Neil L. Berinstein, MD, professor, University of Toronto, Sunnybrook Health Sciences Centre, discusses combination treatments for patients with high-risk or recurrent follicular lymphoma.
High-dose therapy and stem cell transplants with immunotherapy is a very valuable treatment for patients with high-risk or recurrent follicular lymphoma, according to Berinstein.
Many patients relapse after their first initial frontline treatment for follicular lymphoma within the first year. However, due to this treatment, patients are now going without requiring further treatment for a median of 8 years, explains Berinstein.
Related Content: